Literature DB >> 8095694

Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.

N Adham1, B Ellerbrock, P Hartig, R L Weinshank, T Branchek.   

Abstract

The present study was undertaken to evaluate the behavior of the rat 5-hydroxytryptamine (5-HT)1B receptor stably expressed in a Y-1 cell line, using both radioligand binding ([125I]iodocyanopindolol) and functional assays (inhibition of forskolin-stimulated cAMP release). The measured EC50 values for agonists were lower than expected from the measured Ki values (e.g., 5-HT, EC50 = 0.49 +/- 0.043, nine experiments; Ki = 5.3 +/- 0.82, four experiments). Furthermore, beta-adrenergic antagonists such as propranolol and pindolol, which have been reported to be partial agonists or antagonists at the 5-HT1B receptors in other systems, were found to be full agonists. To investigate the relationship between receptor occupancy and inhibition of cAMP release (and hence the degree of receptor reserve), we used the irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). EEDQ treatment shifted the dose-response curve for 5-HT to the right by 6-7-fold, accompanied by a reduction (30-50%) in maximal response. Analysis of the data by the method of Furchgott revealed a very steep hyperbolic relationship between receptor occupancy and response for 5-HT, with 92 +/- 1.4% (three experiments) receptor reserve at the 50% maximal response level. In contrast to its effect on 5-HT, EEDQ treatment did not significantly shift the dose-response curves for pindolol; rather, only the maximal responses were reduced and a linear relationship was found between receptor occupancy and response for this compound. According to classical receptor theory these data indicate that pindolol is a partial agonist, relative to 5-HT, but because of the high density of 5-HT1B receptors in this system the difference between the intrinsic activities of the two drugs is masked. Therefore, one has to be cautious when interpreting functional data in transfected systems that often display large receptor reserve.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095694

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-ht7 receptor in rat brain.

Authors:  E L Gustafson; M M Durkin; J A Bard; J Zgombick; T A Branchek
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

2.  Pharmacological characterizations of recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes.

Authors:  J M Zgombick; L E Schechter; N Adham; S A Kucharewicz; R L Weinshank; T A Branchek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 3.  A cellular perspective of bias at G protein-coupled receptors.

Authors:  Thomas J Fernandez; Monica De Maria; Braden T Lobingier
Journal:  Protein Sci       Date:  2020-04-27       Impact factor: 6.725

4.  Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding.

Authors:  H Giles; S J Lansdell; M L Bolofo; H L Wilson; G R Martin
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

5.  Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats.

Authors:  Y Nishimura
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  5-Hydroxytryptamine 5-HT1B receptors inhibiting cyclic AMP accumulation in rat renal mesangial cells.

Authors:  P Schoeffter; J Pfeilschifter; I Bobirnac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

7.  Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.

Authors:  S P Baker; P J Scammells; L Belardinelli
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

8.  Irreversible antagonism of 5HT2c receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).

Authors:  Y G Ni; N Camacho; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

9.  Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways.

Authors:  N Adham; L A Borden; L E Schechter; E L Gustafson; T L Cochran; P J Vaysse; R L Weinshank; T A Branchek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

10.  Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.

Authors:  James J Lu; Willma E Polgar; Anika Mann; Pooja Dasgupta; Stefan Schulz; Nurulain T Zaveri
Journal:  Mol Pharmacol       Date:  2021-05-06       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.